GSK announces that Cerex®, a vaccine to prevent cervical cancer in women, has been approved for marketing in China

GlaxoSmithKline Cervarix - human papillomavirus (HPV) infection is the main cause of cervical cancer HPV vaccination will provide protection for the majority of Chinese women at risk of HPV infection GlaxoSmithKline (GSK) today announced that (HPV vaccine [type 16 and 18]) was approved by China food and Drug Administration (CFDA) and became the first approved HPV vaccine for cervical cancer prevention in China HPV vaccination and cervical cancer screening together will provide a better way for Chinese women to prevent cervical cancer Hirsch ® is registered in China for vaccination of women aged 9 to 25 years, using a three dose vaccination program, and is expected to be officially launched early next year A six-year clinical trial of Hirsch ® in China included more than 6000 subjects who were vaccinated and controlled respectively The results show that the vaccine has a high protective effect and a satisfactory benefit risk ratio in the prevention of some carcinogenic HPV related cervical diseases The results are consistent with data from global clinical studies The approval of Hirsch ® means that Chinese girls and young women will have the chance to prevent the deadly disease through vaccination Mr Ji Haiwei, senior vice president of GSK and general manager of prescription drugs and vaccines in China / Hong Kong, said, "improving the accessibility of our innovative drugs and vaccines is a clear strategy of GSK China We believe that through cooperation with relevant government departments, we will improve the accessibility of Chinese people to innovative vaccines like Hirsch ® To achieve this goal, we will explore innovative pricing methods to support the inclusion of Hirsch ® in the national immunization program "In addition to improving the accessibility of vaccines, ensuring the quality of vaccines has always been our top priority GSK China fully supports the newly revised regulations on vaccine distribution and vaccination recently issued by the Chinese government This is not only in the interests of the Chinese people, but also in line with our commitment to "based on China, join hands with China and serve China" Cervical cancer is the second most common cancer among Chinese women aged 15 to 44, with about 130000 new cases per year Every year, China accounts for more than 28% of cervical cancer cases in the world Globally, on average, one new case is detected every minute, and one woman dies of cervical cancer every two minutes Therefore, the introduction of HPV vaccination in China will reduce the incidence rate of cervical cancer and precancerous lesions and reduce the burden of disease GlaxoSmithKline Cervarix